|
KMID : 0378019920350060101
|
|
New Medical Journal
1992 Volume.35 No. 6 p.101 ~ p.105
|
|
|
Clinical Evaluation of Cefminox (Meicelin^(®)) in Biliary & Gastrointestinal Tract Infections
|
|
조원일/Cho, Won Il
장석균/이재학/주상용/Chang, Suk Kyun/Lee, Jai Ilak/Choo, Sang Yong
|
|
|
Abstract
|
|
|
Cefminox (Meicelin®) is a cephamycin antibiotic having a D-amino acid structure in the side chain at its C7 position. It has antibacterial activity against gram negative to anaerobic bacteria and is stable to ?-lactamase producing bacteria.
We evaluated the effectivity and the safety of Cefminox (Meicelin®) in 31 incidences of 22 cases with biliary and gastrointestinal tract infections.
The results were;
1 The incidences of biliary diseases were 1 (4.5%) in cholangitis with cholangio CA, 1 (4.5%) in ruptured GB empyema due to GB CA with resultant right subphrenic abscess, 4.(18.2%) in chronic cholecystitis, 3(13.6%) in GB empyema and 2(9.1%) in liver abscess. That of gastrointestinal infections were 2 (9.1%) in enterocutaneous fistula, 4 (18.2%) in intraabdominal abscess, 3 (13.6%) in periappendiceal abscess and 2 (9.1%) in wound abscess.
2. The isolated organisms were E. coli 8 (26.0%), A. hemostrepto. 4 (13.0%), P. aeruginosa 5 (16.0%), Kleb.. oxytoca 5 (16.0%), Ent. cloacae 2 (6.5%), Sta. aureus 2 (6.5%), P.vulgaris 1 (3.2%), Serra. marcescens 1 (3.2%), P. rettigerii 1 (3.2%), A. anitratus 1(3.2%) and P. maltophilia 1 (3.2%).
3. Of the 31 incidences of isolated organisms in abscess culture, 16 cases (51.6%) were sensitive to Cefminox (Meicelin®) and 5 cases (16.1%) showed intermittent sensitivity. 10 cases (32.3%) were resistant.
4. Efficacies were excellent in 13 cases (59.1%), good in 4 cases (18.2%), fair in 4 cases (18.2%) and negligible in 1 case (4.5%). So, overall efficiency rate was 77.3%.
5. No significant side effect was noted during or after Cefminox (Meicelin®) treatment except 1 case of eosinophilia that was normalized soon after discontinuation of Cefminox (Meicelin®).
So; Cefminox (Meicelin®) could be used effectively and safely in biliary and gastrointestinal tract infections.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|